- On a consolidated basis, operating losses narrowed by KRW 45.0 billion on improved profitability at subsidiary SK Bioscience
- On a separate (parent-company) basis, revenue of KRW 1.4404 trillion and operating profit of KRW 95.7 billion
SK Chemicals reported its 2025 results, delivering roughly 36% growth despite a downturn in the global chemical industry.
SK Chemicals (CEO: Ahn Jae-hyun) disclosed in a regulatory filing on the 6th that, on a consolidated basis, it posted 2025 revenue of KRW 2.3652 trillion and an operating loss of KRW 200 million.
Revenue increased 36.2% year on year, driven by higher sales of key products such as copolyesters and pharmaceuticals, along with top-line growth at subsidiary SK Bioscience. As profitability at SK Bioscience improved, SK Chemicals narrowed its operating loss by KRW 45.0 billion from the prior year.
On a separate (parent-company) basis, revenue rose 7.45% year on year to KRW 1.4404 trillion. Operating profit, however, declined 13.84% to KRW 95.7 billion due to higher raw material costs.
An SK Chemicals representative said, “Even amid a challenging market environment marked by a global economic slowdown and industry headwinds, we are enhancing the competitiveness of our core businesses and sustaining top-line growth. We will establish a stable operating system that enables proactive responses to market volatility, while continuing to strengthen our fundamental competitiveness and drive management efficiency.
[Photo caption: SK Chemicals headquarters in Pangyo, Seongnam, Gyeonggi Province, Korea]